Cargando…

Should We Treat Prehypertension in Diabetes?: What are the cons?

Detalles Bibliográficos
Autor principal:	Grossman, Ehud
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Hypertension and Diabetes Debates
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811462/ https://www.ncbi.nlm.nih.gov/pubmed/19875565 http://dx.doi.org/10.2337/dc09-S324

Ejemplares similares

How to Define Prehypertension in Diabetes/Metabolic Syndrome
por: Leibowitz, Avshalom, et al.
Publicado: (2009)

Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?
por: Nilsson, Peter M.
Publicado: (2009)

Treatment of Prehypertension in Diabetes and Metabolic Syndrome: What are the pros?
por: Segura, Julian, et al.
Publicado: (2009)

White-Coat Hypertension Should Not Be Treated in Subjects With Diabetes
por: Bursztyn, Michael, et al.
Publicado: (2009)

Should White-Coat Hypertension in Diabetes Be Treated? Pro
por: Mancia, Giuseppe, et al.
Publicado: (2009)

Hypertension and Diabetes: What are the pros to treating early surrogates?
por: Schmieder, Roland E.
Publicado: (2009)

Should 24-h Ambulatory Blood Pressure Monitoring Be Done in Every Patient With Diabetes?
por: Parati, Gianfranco, et al.
Publicado: (2009)

Blood Pressure: The Lower, the Better: The con side
por: Grossman, Ehud
Publicado: (2011)

Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension
por: Grossman, Ehud
Publicado: (2013)

RAS Blockade for Every Diabetic Patient: Pro and Con
por: Ruilope, Luis M., et al.
Publicado: (2011)

Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011)

Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future?
por: Lopez, Emmanuel, et al.
Publicado: (2013)

What should we expect from Switzerland’s compulsory dental insurance reform?
por: di Bella, Enrico, et al.
Publicado: (2018)

Ethics review of big data research: What should stay and what should be reformed?
por: Ferretti, Agata, et al.
Publicado: (2021)

Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?
por: Macfarlane, Alastair, et al.
Publicado: (2018)

Endothelial Factors and Diabetic Nephropathy
por: Karalliedde, Janaka, et al.
Publicado: (2011)

Evidence-based ethics – What it should be and what it shouldn't
por: Strech, Daniel
Publicado: (2008)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses
por: Ginsberg, Henry N.
Publicado: (2011)

Antihypertensive Treatment and Blood Pressure in Diabetic and Nondiabetic Patients: The lower, the better?
por: Mancia, Giuseppe, et al.
Publicado: (2011)

Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment
por: Ritz, Eberhard
Publicado: (2011)

What else can we do to prevent diabetic retinopathy?
por: Simó, Rafael, et al.
Publicado: (2023)

Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes
por: Parati, Gianfranco, et al.
Publicado: (2013)

Should we maintain baby hatches in our society?
por: Asai, Atsushi, et al.
Publicado: (2013)

Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension: Importance of early and sustained implementation of effective treatment strategies
por: Parati, Gianfranco, et al.
Publicado: (2011)

Diets for patients with chronic kidney disease, should we reconsider?
por: Mitch, William E., et al.
Publicado: (2016)

Uncontrolled hypertension in patients with type 2 diabetes: What are the correlates?
por: Rabizadeh, Soghra, et al.
Publicado: (2021)

Should we restrict erythrocyte transfusion in early goal directed protocols?
por: Meybohm, Patrick, et al.
Publicado: (2015)

Physical activity recommendations for health: what should Europe do?
por: Oja, Pekka, et al.
Publicado: (2010)

Resuming the discussion of AMSTAR: What can (should) be made better?
por: Wegewitz, Uta, et al.
Publicado: (2016)

Observational studies - should we simply ignore them in assessing transfusion outcomes?
por: Trentino, Kevin, et al.
Publicado: (2016)

Lower is better in hypertension, but how low should blood pressure be targeted?
por: Touyz, Rhian M.
Publicado: (2016)

Should we reframe how we think about physical activity and sedentary behaviour measurement? Validity and reliability reconsidered
por: Kelly, Paul, et al.
Publicado: (2016)

What is presumed when we presume consent?
por: Pierscionek, Barbara K
Publicado: (2008)

Same same but different: why we should care about the distinction between professionalism and ethics
por: Salloch, Sabine
Publicado: (2016)

Sexual and reproductive health self-care in humanitarian and fragile settings: where should we start?
por: Tran, Nguyen Toan, et al.
Publicado: (2021)

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
por: Schrader, J, et al.
Publicado: (2009)

Individualization of Antihypertensive Drug Treatment
por: Mancia, Giuseppe, et al.
Publicado: (2013)

Intolerance to Statins: Mechanisms and Management
por: Bitzur, Rafael, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0bgscdf163c8p16a02t0tb6f95